
CF PharmTech
No. 16, Hucundang Road, Suzhou, Jiangsu, 215143, China
Overview
CF PharmTech is a fully integrated specialty pharmaceutical company that develops and manufactures inhalation products and respiratory drugs. The company focuses on treatments for respiratory diseases and operates facilities for drug development and production. It raised a US$50M Series F financing to support its programs. The company followed a US$90M Series E in January 2020; together those rounds amount to nearly US$140M of equity investment within six months. CF PharmTech says it will use the Series F proceeds to accelerate commercialization of its inhalation products. The company positions itself to provide affordable, high-quality respiratory drugs globally. CF PharmTech is a pharmaceutical company dedicated to respiratory health, with state-of-the-art R&D and manufacturing facilities for inhalation products. The company has built a pipeline of more than 20 products aimed at China and global markets. It raised a $90M Series E to advance its product pipeline. The firm intends to use the funds to bring products in its pipeline to market. CF PharmTech operates from Shuzhou, China, and emphasizes inhalation therapeutics and related manufacturing capabilities. The article does not disclose revenue or user metrics. CF PharmTech is a Suzhou, China-based specialty pharmaceutical company focused on the development, manufacturing and commercialization of inhalation products, including metered dose inhalers, inhalation powders, nasal sprays and blow-fill-seal products. The company has established research and manufacturing facilities to advance its product development. Founded by seasoned industry experts and entrepreneurs from the US pharmaceutical industry, CF PharmTech also provides CDMO services. It intends to use new financing to expedite submission of its product pipeline for regulatory approvals in China and abroad and to expand its CDMO services to international clients. The company raised $65M in a Series D financing to support these plans.
- Total raised
- $205M
- Funding rounds
- 3
- Latest round
- Series F
- Latest activity
- Jul 2020
Industries
- Health Care
- Manufacturing
- Pharmaceutical
Recent funding
Series F
Jul 2020
$50M
Series E
Jan 2020
$90M
Series D
Aug 2017
$65M